FDA announces major reforms to streamline biosimilar approvals, potentially saving Americans billions on prescription drug ...
Capital Market on MSN
Alembic Pharma gains after Q2 PAT climbs 20% YoY to Rs 185 cr
Revenue from operations grew 15.90% year on year (YoY) to Rs 1,910.15 crore in the quarter ended 30 September 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback